Literature DB >> 31707054

The role of toll-like receptors in myocardial toxicity induced by doxorubicin.

Cai Xinyong1, Zeng Zhiyi1, Hong Lang1, Yan Peng1, Wu Xiaocheng1, Zhang Ping2, Shao Liang3.   

Abstract

Doxorubicin is an effective antitumor drug commonly used in the treatment of a wide variety of cancers. However, doxorubicin may cause cardiac toxicity, which can cause congestive heart failure in severe cases, and this seriously limits its clinical application. It is believed that doxorubicin promotes the formation of reactive oxygen species, inducing oxidative stress, and at the same time, reduces the content of antioxidant substances in cardiac tissues, causing adverse effects. Toll-like receptors (TLRs) are biomolecules expressed on the surfaces of macrophages, dendritic cells, and epithelial cells that can recognize various types of pathogen-related or damage-related molecular patterns. In recent years, a large number of studies have confirmed that TLRs play important roles in the cardiac toxicity induced by doxorubicin. This review aimed to explore the role of TLRs in the cardiac toxicity induced by doxorubicin and provide possible solutions.
Copyright © 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiotoxicity; Doxorubicin; Toll-like receptors

Year:  2019        PMID: 31707054     DOI: 10.1016/j.imlet.2019.11.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  Long-noncoding RNA MALAT1 sponges microRNA-92a-3p to inhibit doxorubicin-induced cardiac senescence by targeting ATG4a.

Authors:  Wenzheng Xia; Hanbin Chen; Congying Xie; Meng Hou
Journal:  Aging (Albany NY)       Date:  2020-05-08       Impact factor: 5.682

Review 2.  Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery.

Authors:  Sepideh Mirzaei; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Negar Azami; Soodeh Hamzehlou; Mahdi Vasheghani Farahani; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Antioxidants (Basel)       Date:  2021-02-26

3.  Laser-triggered combination therapy by iron sulfide-doxorubicin@functionalized nanozymes for breast cancer therapy.

Authors:  Shipeng Ning; Yang Zheng; Kun Qiao; Guozheng Li; Qian Bai; Shouping Xu
Journal:  J Nanobiotechnology       Date:  2021-10-27       Impact factor: 10.435

4.  Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer.

Authors:  Lei Wang; Liping Liang; Shuzhen Shi; Chao Wang
Journal:  Appl Bionics Biomech       Date:  2022-02-22       Impact factor: 1.781

5.  Sonicated Bordetella bronchiseptica Bacterin Can Protect Dendritic Cells from Differential Cytotoxicity Caused by Doxorubicin and Vincristine and Enhance Their Antigen-Presenting Capability.

Authors:  Ji Yun Sung; Hong-Gu Joo
Journal:  Curr Issues Mol Biol       Date:  2022-07-06       Impact factor: 2.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.